Cohance Lifesciences reports 13% revenue growth in Q1 FY26

During the quarter, construction began on a US$ 10 million bioconjugation cGMP suite at NJ Bio’s Princeton site

Cohance to invest $10 million to expand cGMP bioconjugation capabilities in US

NJ Bio is currently executing a major new program for an existing innovator customer with multiple ADC candidates in their pipeline

Boehringer’s lung cancer medicine gets FDA approval

FDA grants accelerated approval to zongertinib for HER2 TKD-Mutated Non-Squamous NSCLC

Revvity launches reagent technology for targeted therapeutics

Innovative plate-based internalization reagents designed to deliver accurate, high-throughput, and scalable insights for GPCR and ADC research

Eli Lilly inaugurates global capability centre in hyderabad to advance AI initiatives

The expansion will bring together talent in AI, data science, and engineering to build the digital foundation needed to accelerate drug discovery and delivery

Sanofi’s GPRC5D monoclonal antibody earns ODD in US for multiple myeloma

Cohance Lifesciences appoints Yann D'Herve as CEO of CDMO Business

His experience includes leadership roles in manufacturing, strategic management, and commercial operations across the pharmaceuticals, healthcare, and specialty chemicals sectors

Datroway approved in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer

First and only TROP2-directed therapy approved in the US for the treatment of lung cancer

Sanner commences manufacturing critical injection-molded components in USA

The GMP-compliant facility with automated environmental monitoring accommodates both white room and class 7 and 8 cleanroom space

Carbogen Amcis enters into a co-investment agreement of CHF 25+ million to expand Swiss sites

This project builds on a previous joint funding agreement between CARBOGEN AMCIS and the same customer in April 2021